Nikolaos Pyrgidis1, Ioannis Vakalopoulos1, Petros Sountoulides2. 1. 1st Department of Urology, Aristotle University of Thessaloniki, 15-17 Agiou Evgeniou Street, TK 55133, Thessaloniki, Greece. 2. 1st Department of Urology, Aristotle University of Thessaloniki, 15-17 Agiou Evgeniou Street, TK 55133, Thessaloniki, Greece. sountp@hotmail.com.
Abstract
PURPOSE: Prostate cancer (PCa) is the commonest non-cutaneous malignancy worldwide and the second cause of cancer death among males in the USA. Approval of the new androgen receptor axis-targeted (ARAT) agents (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) has altered the course of advanced PCa. We aimed to assess the endocrine and metabolic adverse events associated with treatment using ARAT compounds. METHODS: We searched the PubMed, Cochrane Library, and Scopus databases from database inception to August 2020. We included randomized controlled trials reporting the endocrine and metabolic side effects of ARAT agents compared to each other or to placebo. RESULTS: Although metastatic PCa remains incurable, ARAT medications combined with androgen deprivation therapy improve overall metastasis-free and progression-free survival in metastatic hormone-sensitive PCa, non-metastatic castration-resistant PCa, and metastatic castration-resistant PCa patients. This benefit comes at the cost of certain endocrine and metabolic consequences. Treatment with abiraterone acetate induces mineralocorticoid excess, hypokalemia, hypertension, elevated liver function tests, insulin resistance, and hyperglycemia. Enzalutamide may induce or worsen hypertension and increase the risk of falls and fractures in elderly patients, while common endocrine adverse events of apalutamide include hypothyroidism, hypertension, and skin rash. On the other hand, darolutamide seems to have a somewhat safer endocrine and metabolic profile. CONCLUSION: Treatment of advanced PCa should be personalized, with administration of a combination of androgen deprivation therapy, ARAT agents, and chemotherapy being based on the patient's safety profile and the risk of side effects.
PURPOSE:Prostate cancer (PCa) is the commonest non-cutaneous malignancy worldwide and the second cause of cancer death among males in the USA. Approval of the new androgen receptor axis-targeted (ARAT) agents (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) has altered the course of advanced PCa. We aimed to assess the endocrine and metabolic adverse events associated with treatment using ARAT compounds. METHODS: We searched the PubMed, Cochrane Library, and Scopus databases from database inception to August 2020. We included randomized controlled trials reporting the endocrine and metabolic side effects of ARAT agents compared to each other or to placebo. RESULTS: Although metastatic PCa remains incurable, ARAT medications combined with androgen deprivation therapy improve overall metastasis-free and progression-free survival in metastatic hormone-sensitive PCa, non-metastatic castration-resistant PCa, and metastatic castration-resistant PCa patients. This benefit comes at the cost of certain endocrine and metabolic consequences. Treatment with abiraterone acetate induces mineralocorticoid excess, hypokalemia, hypertension, elevated liver function tests, insulin resistance, and hyperglycemia. Enzalutamide may induce or worsen hypertension and increase the risk of falls and fractures in elderly patients, while common endocrine adverse events of apalutamide include hypothyroidism, hypertension, and skin rash. On the other hand, darolutamide seems to have a somewhat safer endocrine and metabolic profile. CONCLUSION: Treatment of advanced PCa should be personalized, with administration of a combination of androgen deprivation therapy, ARAT agents, and chemotherapy being based on the patient's safety profile and the risk of side effects.
Authors: Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni Journal: Eur Urol Date: 2014-01-09 Impact factor: 20.096
Authors: A Patrikidou; Y Loriot; J-C Eymard; L Albiges; C Massard; E Ileana; M Di Palma; B Escudier; K Fizazi Journal: Prostate Cancer Prostatic Dis Date: 2014-10-14 Impact factor: 5.554
Authors: David E Neal; Chris Metcalfe; Jenny L Donovan; J Athene Lane; Michael Davis; Grace J Young; Susan J Dutton; Eleanor I Walsh; Richard M Martin; Tim J Peters; Emma L Turner; Malcolm Mason; Richard Bryant; Prasad Bollina; James Catto; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Peter Holding; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Jon Oxley; Alan Paul; Edgar Paez; Derek J Rosario; Edward Rowe; John Staffurth; Doug G Altman; Freddie C Hamdy Journal: Eur Urol Date: 2019-11-24 Impact factor: 20.096
Authors: Gwenaelle Gravis; Karim Fizazi; Florence Joly; Stéphane Oudard; Franck Priou; Benjamin Esterni; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Fréderic Rolland; Christine Théodore; Gael Deplanque; Jean Marc Ferrero; Damien Pouessel; Loïc Mourey; Philippe Beuzeboc; Sylvie Zanetta; Muriel Habibian; Jean François Berdah; Jerome Dauba; Marjorie Baciuchka; Christian Platini; Claude Linassier; Jean Luc Labourey; Jean Pascal Machiels; Claude El Kouri; Alain Ravaud; Etienne Suc; Jean Christophe Eymard; Ali Hasbini; Guilhem Bousquet; Michel Soulie Journal: Lancet Oncol Date: 2013-01-08 Impact factor: 41.316
Authors: E David Crawford; Axel Heidenreich; Nathan Lawrentschuk; Bertrand Tombal; Antonio C L Pompeo; Arturo Mendoza-Valdes; Kurt Miller; Frans M J Debruyne; Laurence Klotz Journal: Prostate Cancer Prostatic Dis Date: 2018-08-21 Impact factor: 5.554
Authors: Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell Journal: J Urol Date: 2017-12-15 Impact factor: 7.450